Plain-English translation of NCT06982352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called for people with atopic dermatitis (eczema) or psoriasis. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body processes it. About 48 people will participate, with half receiving the actual medication and half receiving a placebo (dummy pill).
Currently, many people with atopic dermatitis and psoriasis have limited treatment options or struggle with side effects from existing medications. This study is exploring whether this new treatment could offer a safer and more effective option for managing these chronic skin conditions.
You likely qualify if…
You likely don't qualify if…
You will visit the study site multiple times for appointments where you'll receive either the new medication or a placebo as an oral dose. You'll also have blood tests and heart monitoring (ECG) done to measure how the medication is working in your body and to check for any side effects. The study involves both outpatient visits and at least one inpatient stay so researchers can closely monitor your safety and how your body responds to the treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Jordan